Impact of Gly389Arg 1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol


Cite item

Full Text

Abstract

Aim. To study в1-adrenoceptor gene (ADRB1) polymorphism on the development and course of chronic heart failure (CHF) and on the efficiency of its treatment with the в-adrenoblocker carvedilol in patients with coronary heart failure.
Subjects and methods. Two hundred and twenty-six patients (149 males and 77 females; mean age 55.9±5.8 years) with CHF, who received continuous basic therapy: angiotensin-converting enzyme inhibitors, a diuretic, an aldosterone antagonist, digoxin, and a в-adrenoblocker, were examined; 68 patients were given for 24 weeks carvedilol (its starting dose was 3.125 mg twice daily with its further adjustment until an individually tolerable dose was achieved). Genotypes were identified by the restriction fragment length polymorphism analysis of polymerase chain reaction products. A control group comprised 136 subjects (63 males and 73 females; mean age 55.9±5.8 years) without signs of cardiovascular disorders, as evidenced by the examination.
Results. In patients with CHF, the Gly allele of the Gly389Arg polymorphic locus of the ADRB1 gene in homozygous state was associated with the high individual risk for CHF, the severity of its clinical manifestations and the nature of its course while carriage of the Arg allele of the Gly39Arg polymorphic locus manifested itself as a protective factor. During long-term carvedilol therapy, CHF patients with the Arg/Arg genotype of the ADRB1 gene were observed to have a more pronounced decrease in the functional class of heart failure, a significant increase in left ventricular ejection, and a decrease in left ventricular end-systolic and end-diastolic sizes as compared with patients with the Gly/Arg genotype.
Conclusion. There were associations of the polymorphism of ADRB1 gene (the Gly39Arg polymorphic locus) with the development and severity of CHF and with the efficacy of therapy with в-adrenoblocker carvedilol.

About the authors

Aleksandr Trofimovich Teplyakov

Sergey Nikolaevich Shilov

Email: sergei@rnp.ru

Ekaterina Nikolaevna Berezikova

Yuliya Yur'evna Torim

Email: ytorim@list.ru

Anatoliy Vasil'evich Efremov

Email: eav48@yandex.ru

Igor' Dmitrievich Safronov

Email: safronov1962@mail.ru

S D Mayanskaya

Email: smayanskaya@mail.ru

Anna Aleksandrovna Popova

Email: ann24@ngs.ru

Elena Nikolaevna Voronina

Email: voronina_l@inbox.ru

Rostislav Sergeevich Karpov

A T Teplyakov

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

S N Shilov

Novosibirsk State Medical University

Novosibirsk State Medical University

E N Berezikova

Novosibirsk State Medical University

Novosibirsk State Medical University

Yu Yu Torim

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

A V Efremov

Novosibirsk State Medical University

Novosibirsk State Medical University

I D Safronov

Novosibirsk State Medical University

Novosibirsk State Medical University

S D Mayanskaya

Kazan State Medical Academy, Russian Agency for Health Care

Kazan State Medical Academy, Russian Agency for Health Care

A A Popova

Novosibirsk State Medical University

Novosibirsk State Medical University

E N Voronina

Novosibirsk Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences

Novosibirsk Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences

R S Karpov

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences

References

  1. Packer M. How should physician view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am. J. Cardiol. 1993; 71: 3C-11C.
  2. Мареев В. Ю. Изменение стратегии лечения хронической сердечной недостаточности. Время b-адреноблокаторов. Кардиология 1998; 12: 4-11.
  3. Мареев В. Ю. Новые возможности в лечении сердечной недостаточности. Полная блокада нейрогуморальных систем. Кардиология 1999; 12: 4-9.
  4. Schwartz K. On the pulse of genetic cardiology. Nat. Genet. 1994; 8: 110-111.
  5. Cambien F., Tiret L. Genetics of cardiovascular diseases. Circulation 2007; 116: 1714-1724.
  6. Bleumink G. S., Schut A. F., Sturkenboom M. C. et al. Genetic polymorphisms and heart failure. Genet. Med. 2004; 6(6): 465-474.
  7. Kitsios G., Zintzaras E. Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis. Am. J. Epidemiol. 2007; 166(6): 619-633.
  8. Snyder E. M., Olson T. P., Johnson B. D. Genetics and pharmacogenetics in heart failure. Curr. Heart Fail. Rep. 2007; 4(3): 139-144.
  9. Баранов В. С., Хавинсон В. Х. Определение генетической предрасположенности к некоторым мультифакториальным заболеваниям. Генетический паспорт. СПб.: Фолиант; 2001.
  10. Le Convoisier P., Park H. Y., Carlson K. M. et al. Impact of genetic polymorphisms on heart failure prognosis. Arch. Mal. Coeur 2003; 96(3): 197-206.
  11. Waagstein F., Caidahl K., Wallentin I. et al. Long-term beta-blockade in dilated cardiomyopathy: effects of short-term and long-term metoprolol followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551-563.
  12. The BEST Steering Committee. Am. J. Cardiol. 1995; 75: 1220-1223.
  13. The International Steering Committee on behalt of the MERIT-HF Study Group. A,. J. Cardiol. 1997; 80 (Suppl. 9B): 54J-58J.
  14. COPERNICUS investigators resource. Basel: F. Hoffman-La Roche Ltd; 2000.
  15. Packer M., Bristow M. R., Cohn J. N. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. Med. 1996; 334: 1349.
  16. Ляхович В. В., Вавилин В. А., Гришанова А. Ю. и др. Фармакогенетика и современная медицина. Вестн. РАМН 2004; 10: 40-45.
  17. Полякова Д. Фармакогенетика: действительность и перспективы. Аптека 2006; 5(526).
  18. Минушкина Л. О., Затейщиков Д. А., Сидоренко Б. А. Индивидуальная чувствительность к антигипертензивным препаратам: генетические аспекты. Кардиология 2005; 7: 58-65.
  19. Humma L. M., Terra S. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am. J. Hlth Syst. Pharm. 2002; 59: 1241-1252.
  20. Маниатис Т., Фрич Э., Сэмбрук Дж. Молекулярное клонирование. М.: Мир; 1984.
  21. Covolo L., Gelatti U., Metra M. Role of b1- and b2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur. Heart J. 2004; 25: 1534-1541.
  22. Nonen S., Okamoto H., Akino N. No positive association between adrenergic receptor variants of б2cDel322-325, b1Ser49, b1Arg389 and the risk for heart failure in the Japanese population. Br. J. Clin. Pharmacol. 2005; 60(4): 414-417.
  23. Humma L. M., Puckett B. J., Richardson H. E. et al. Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am. J. Cardiol. 2001; 88: 1034-1037.
  24. Bengtsson K., Melander O., Orho-Melander M. et al. Polymorphism in the b1-adrenergic receptor gene and hypertension. Circulation 2001; 104: 187-190.
  25. Mason D. A., Moore J. D., Green S. A. et al. A gain-of-function polymorphism in a G-protein coupling domain of the human1-adrenergic receptor. J. Biol. Chem. 1999; 274: 12 670?12 674.
  26. O'Shaughnessy K. M., Fu B., Dickerson C. et al. The gain - of - function G389R variant of the в1-adrenoreceptor does not influence blood pressure or heart rate response to в - blockade in hypertensive subjects. Clin. Sci. 2000; 99: 233-238.
  27. Johnson J. A., Zineh I., Puckett B. J. et al. Beta 1 - adrenergic receptor gene polymorphism and antihypertensive response o metoprolol. Clin. Pharmacol. Ther. 2003; 74(4): 299-302.
  28. White H. L., Boer R. A., Maqbool A. et al. Mutation of the beta-1 adrenergic receptor (Arg389Gly) polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail 2003; 5(4): 463-468.
  29. Terra S. G., Pauly D. F., Lee C. R. et al. Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin. Pharmacol. Ther. 2005; 77(3): 127-137.
  30. Терещенко С. Н., Джаиани Н. А., Моисеев В. С. Генетические аспекты хронической сердечной недостаточности. Тер. арх. 2000; 4: 75-77.
  31. Коган-Пономарев М. Я. Клиническое значение некоторых факторов транскрипции генов при болезнях сердца. Кардиология 2004; 1: 66-70.
  32. Затейщиков Д. А., Чумакова О. С., Затейщикова А. А. и др. Генетические предикторы неблагоприятного течения заболевания у больных ИБС высокого риска по данным 2-летнего наблюдения. Кардиология 2004; 12: 16-22.

Copyright (c) 2010 Teplyakov A.T., Shilov S.N., Berezikova E.N., Torim Y.Y., Efremov A.V., Safronov I.D., Mayanskaya S.D., Popova A.A., Voronina E.N., Karpov R.S., Teplyakov A.T., Shilov S.N., Berezikova E.N., Torim Y.Y., Efremov A.V., Safronov I.D., Mayanskaya S.D., Popova A.A., Voronina E.N., Karpov R.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies